New Federal Incentives for Diversity in Clinical Trials
Thomas J. Hwang, Otis W. Brawley
Abstract
Too often, the clinical trials that provide the evidence on which drug approvals and medical practices are based fail to offer adequate support for medical decision making, because they include inappropriately narrow and homogeneous study populations. The Journal has begun requiring investigators to report on the representativeness of their study participants, but what are the next steps? In this Perspective Roundtable,
Topics & Concepts
Representativeness heuristicDiversity (politics)IncentiveClinical trialPerspective (graphical)HomogeneousMedicinePsychologyActuarial scienceFamily medicinePolitical scienceBusinessSocial psychologyComputer scienceLawEconomicsPathologyThermodynamicsPhysicsMicroeconomicsArtificial intelligenceEthics in Clinical ResearchBiomedical Ethics and RegulationHealth Systems, Economic Evaluations, Quality of Life